Advertisement
UK markets close in 2 hours 24 minutes
  • FTSE 100

    8,077.63
    +32.82 (+0.41%)
     
  • FTSE 250

    19,772.28
    -27.44 (-0.14%)
     
  • AIM

    755.00
    +0.13 (+0.02%)
     
  • GBP/EUR

    1.1640
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.2443
    -0.0010 (-0.08%)
     
  • Bitcoin GBP

    53,175.76
    +9.27 (+0.02%)
     
  • CMC Crypto 200

    1,434.66
    +10.56 (+0.74%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    83.31
    -0.05 (-0.06%)
     
  • GOLD FUTURES

    2,335.50
    -6.60 (-0.28%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,150.71
    +13.06 (+0.07%)
     
  • CAC 40

    8,135.88
    +30.10 (+0.37%)
     

Worldwide Contraceptives Industry to 2029 - by Product, Device and Region

Company Logo
Company Logo

Dublin, July 20, 2022 (GLOBE NEWSWIRE) -- The "Contraceptives Market Analysis by Product (Topical, Oral Contraceptive Pills, Injectable Contraceptives), by Device (Male Condoms, Diaphragms, Female Condoms, Vaginal Rings, Sub Dermal Implants, Intra-Uterine Devices), and by Region - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The global contraceptives market size is estimated to be USD 23.52 billion in 2021 and is expected to witness a CAGR of 6.31% during the forecast period.

NGO and government initiatives to encourage use of contraceptive methods is a key driver for the growth of the global contraceptives market. Additionally, rising need for checking unwanted pregnancy and increase in awareness about contraceptives worldwide are some of the other drivers propelling the market growth. Nevertheless, health risks related with the usage of various contraceptive methods and rapid growth in aging population and rise in cases of infertility are expected to restrain the global market growth.

By Product

Based on product, the market is segmented into topical contraceptives, oral contraceptive pills, and injectable contraceptives. In 2021, the oral contraceptive pills segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to widespread use of these products and effectiveness in avoiding unplanned pregnancy worldwide. Injectable contraceptives segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the increasing demand for these contraceptives as they last from 8 to 13 weeks.

By Device

ADVERTISEMENT

Based on device, the market is segmented into contraceptive sponges, male condoms, diaphragms, female condoms, vaginal rings, sub dermal implants, and intra-uterine devices. In 2021, the intra-uterine devices segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to a rise in number of gynaecologists choosing these devices for contraception worldwide. Male condoms segment projected to grow at a profitable CAGR during the forecast period. This is attributed to a substantially huge consumer base, high usage and government programs generating awareness about them in the developing economies.

Regional Insights

In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the increase in occurrence of abortion, rise in population of women inside the age group of 15-44 years, growth in initiatives from government, accessibility of technological advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the increasing awareness among individuals, growing government initiatives relating to sex education for individuals are the major factors in this region.

Competitor Insights

Some of the key players in the contraceptives market are The Female Health Company (U.K.); Teva Pharmaceutical Industries Ltd. (Israel); Reckitt Benckiser Plc (U.K.); Pfizer, Inc. (U.S.); Mayer Laboratories, Inc. (U.S.); Cooper Surgical (U.S.); Church & Dwight Co. Inc. (U.S.); Actavis plc (U.S.); Merck & Co. (U.S.); and Ansell Limited (Australia).

The leading players operating in the contraceptives industry are adopting various strategies including R&D investments, adaption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share. This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029.

Market Segmentation

The contraceptives market report is categorized into the following segments and subsegments:

By Product (Revenue, USD Billion, 2021 - 2029)

  • Topical contraceptives

  • Oral contraceptive pills

  • Injectable contraceptives

By Device (Revenue, USD Billion, 2021 - 2029)

  • Contraceptive sponges

  • Male condoms

  • Diaphragms

  • Female condoms

  • Vaginal rings

  • Subdermal implants

  • Intra-uterine devices

  • Copper Intra-uterine devices

  • Hormonal intra-uterine devices

By Region (Revenue, USD Billion, 2021 - 2029)

North America

  • U.S.

  • Canada

Europe

  • Germany

  • France

  • UK

  • Spain

  • Italy

  • Russia

  • Rest of Europe

Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Rest of APAC

Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of LATAM

Middle East & Africa

  • South Africa

  • Saudi Arabia

  • Rest of MEA



Key Topics Covered:

1. Research Methodology

2. Introduction: Contraceptives

3. Executive Summary
3.1.Global Market Scenario
3.2.Segment Market Scenario
3.3.Geographic Market Scenario
3.4.COVID-19 Impact
3.5.Competitive Landscape

4. Market Dynamics

5. Market Environment Analysis
5.1.Porter's 5 Forces Analysis
5.2.PESTEL Analysis
5.3.Value Chain Analysis
5.4.SWOT Analysis
5.5.Benchmark

6. COVID-19 Impact Analysis: Contraceptives Market
6.1.COVID-19: Overview
6.2.COVID-19 Impact on the Global Market
6.3.COVID-19 Impact on the Regional Markets

7. Market Analysis by Product
7.1.Topical contraceptives
7.1.1.Topical contraceptives Market Forecast, 2021-2029 (USD Million)
7.2.Oral contraceptive pills
7.2.1.Oral contraceptive pills Market Forecast, 2021-2029 (USD Million)
7.3.Injectable contraceptives
7.3.1.Injectable contraceptives Market Forecast, 2021-2029 (USD Million)

8. Market Analysis by Device
8.1.Contraceptive sponges
8.1.1.Contraceptive sponges Market Forecast, 2021-2029 (USD Million)
8.2.Male condoms
8.2.1.Male condoms Market Forecast, 2021-2029 (USD Million)
8.3.Diaphragms
8.3.1.Diaphragms Market Forecast, 2021-2029 (USD Million)
8.4.Female condoms
8.4.1.Female condoms Market Forecast, 2021-2029 (USD Million)
8.5.Vaginal rings
8.5.1.Vaginal rings Market Forecast, 2021-2029 (USD Million)
8.6.Subdermal implants
8.6.1.Subdermal implants Market Forecast, 2021-2029 (USD Million)
8.7.Intra-uterine devices
8.7.1.Intra-uterine devices Market Forecast, 2021-2029 (USD Million)

9. Regional Market Analysis
9.1.Regional Market Trends
9.2.Regional Market: Comparative Analysis

10. North America Contraceptives Market

11. Europe Contraceptives Market

12. Asia Pacific Contraceptives Market

13. Latin America Contraceptives Market

14. MEA Contraceptives Market

15. Competitor Analysis
15.1.Market Share Analysis, 2021 & 2029
15.2.Competitive Mapping
15.3.Key Players Market Place Analysis
15.4.Major Recent Developments

16. Company Profiles
16.1.The Female Health Company (U.K.)
16.1.1.Company Snapshot
16.1.2.Company Overview
16.1.3.Financials
16.1.4.Product Benchmarking
16.1.5.Recent Developments
16.2.Teva Pharmaceutical Industries Ltd. (Israel)
16.2.1.Company Snapshot
16.2.2.Company Overview
16.2.3.Financials
16.2.4.Product Benchmarking
16.2.5.Recent Developments
16.3.Pfizer, Inc. (U.S.)
16.3.1.Company Snapshot
16.3.2.Company Overview
16.3.3.Financials
16.3.4.Product Benchmarking
16.3.5.Recent Developments
16.4.Mayer Laboratories, Inc. (U.S.)
16.4.1.Company Snapshot
16.4.2.Company Overview
16.4.3.Financials
16.4.4.Product Benchmarking
16.4.5.Recent Developments
16.5.Cooper Surgical (U.S.)
16.5.1.Company Snapshot
16.5.2.Company Overview
16.5.3.Financials
16.5.4.Product Benchmarking
16.5.5.Recent Developments
16.6.Church & Dwight Co. Inc. (U.S.)
16.6.1.Company Snapshot
16.6.2.Company Overview
16.6.3.Financials
16.6.4.Product Benchmarking
16.6.5.Recent Developments
16.7.Actavis plc (U.S.)
16.7.1.Company Snapshot
16.7.2.Company Overview
16.7.3.Financials
16.7.4.Product Benchmarking
16.7.5.Recent Developments
16.8.Merck & Co. (U.S.)
16.8.1.Company Snapshot
16.8.2.Company Overview
16.8.3.Financials
16.8.4.Product Benchmarking
16.8.5.Recent Developments
16.9.Ansell Limited (Australia)
16.9.1.Company Snapshot
16.9.2.Company Overview
16.9.3.Financials
16.9.4.Product Benchmarking
16.9.5.Recent Developments
16.10.Dilon Technologies, Inc. (US)
16.10.1.Company Snapshot
16.10.2.Company Overview
16.10.3.Financials
16.10.4.Product Benchmarking
16.10.5.Recent Developments
16.11.Planmed Oy (Finland)
16.11.1.Company Snapshot
16.11.2.Company Overview
16.11.3.Financials
16.11.4.Product Benchmarking
16.11.5.Recent Developments
16.12.Delphinus Medical Technologies, Inc. (US)
16.12.1.Company Snapshot
16.12.2.Company Overview
16.12.3.Financials
16.12.4.Product Benchmarking
16.12.5.Recent Developments

17.Conclusion & Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/g41cfg

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900